Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis.

Zheng W, Medeiros LJ, Young KH, Goswami M, Powers L, Kantarjian HH, Thomas DA, Cortes JE, Wang SA.

Leuk Lymphoma. 2014 Mar;55(3):624-7. doi: 10.3109/10428194.2013.820293.

2.

Lymphoblastic lymphoma.

Cortelazzo S, Ponzoni M, Ferreri AJ, Hoelzer D.

Crit Rev Oncol Hematol. 2011 Sep;79(3):330-43. doi: 10.1016/j.critrevonc.2010.12.003. Review.

PMID:
21273093
3.

Molecular diagnosis and clinical relevance of t(9;22), t(4;11) and t(1 ;19) chromosome abnormalities in a consecutive group of 141 adult patients with acute lymphoblastic leukemia.

Rambaldi A, Attuati V, Bassan R, Neonato MG, Viero P, Battista R, Di Bona E, Rossi G, Pogliani E, Ruggeri M, Amaru R, Rivolta A, Giudici G, Biondi A, Barbui T.

Leuk Lymphoma. 1996 May;21(5-6):457-66.

PMID:
9172811
4.

CD30 expression in high-risk acute myeloid leukemia and myelodysplastic syndromes.

Zheng W, Medeiros LJ, Hu Y, Powers L, Cortes JE, Ravandi-Kashani F, Kantarjian HH, Wang SA.

Clin Lymphoma Myeloma Leuk. 2013 Jun;13(3):307-14. doi: 10.1016/j.clml.2012.12.006.

5.

Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364.

Czuczman MS, Dodge RK, Stewart CC, Frankel SR, Davey FR, Powell BL, Szatrowski TP, Schiffer CA, Larson RA, Bloomfield CD.

Blood. 1999 Jun 1;93(11):3931-9.

6.

CD66c expression in B-cell acute lymphoblastic leukemia: strength and weakness.

Guillaume N, Penther D, Vaida I, Gruson B, Harrivel V, Claisse JF, Capiod JC, Lefrere JJ, Damaj G.

Int J Lab Hematol. 2011 Feb;33(1):92-6. doi: 10.1111/j.1751-553X.2010.01254.x.

PMID:
20666852
7.

Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases.

Raponi S, De Propris MS, Intoppa S, Milani ML, Vitale A, Elia L, Perbellini O, Pizzolo G, Foá R, Guarini A.

Leuk Lymphoma. 2011 Jun;52(6):1098-107. doi: 10.3109/10428194.2011.559668.

PMID:
21348573
8.

Residual bone marrow leukemic progenitor cell burden after induction chemotherapy in pediatric patients with acute lymphoblastic leukemia.

Uckun FM, Stork L, Seibel N, Sarquis M, Bedros C, Sather H, Sensel M, Reaman GH, Gaynon PS.

Clin Cancer Res. 2000 Aug;6(8):3123-30.

9.

Precursor B-cell lymphoblastic lymphoma: a predominantly extranodal tumor with low propensity for leukemic involvement.

Lin P, Jones D, Dorfman DM, Medeiros LJ.

Am J Surg Pathol. 2000 Nov;24(11):1480-90.

PMID:
11075849
10.

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Foà R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propris MS, Elia L, Paoloni F, Fazi P, Cimino G, Nobile F, Ferrara F, Castagnola C, Sica S, Leoni P, Zuffa E, Fozza C, Luppi M, Candoni A, Iacobucci I, Soverini S, Mandelli F, Martinelli G, Baccarani M; GIMEMA Acute Leukemia Working Party..

Blood. 2011 Dec 15;118(25):6521-8. doi: 10.1182/blood-2011-05-351403.

11.

Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia.

Coustan-Smith E, Kitanaka A, Pui CH, McNinch L, Evans WE, Raimondi SC, Behm FG, Aricò M, Campana D.

Blood. 1996 Feb 1;87(3):1140-6.

12.

Study of gene expression of CD30 variant (CD30v) and CD30 ligand (CD30L) in acute leukemia.

Essa EA, El Halim SM, Abo-Elenin A, El Bendary A, Abdou SH, Farag W.

Egypt J Immunol. 2007;14(1):11-20.

PMID:
18689277
13.

Expression of CD66c and CD25 in acute lymphoblastic leukemia as a predictor of the presence of BCR/ABL rearrangement.

Owaidah TM, Rawas FI, Al Khayatt MF, Elkum NB.

Hematol Oncol Stem Cell Ther. 2008 Jan-Mar;1(1):34-7.

PMID:
20063526
14.

Expression of CD25 is a specific and relatively sensitive marker for the Philadelphia chromosome (BCR-ABL1) translocation in pediatric B acute lymphoblastic leukemia.

Gaikwad AS, Donohue RE, Elghetany MT, Sheehan AM, Lu XY, Gramatges MM, McClain KL, Mistretta TA, Punia JN, Moore TJ, Goltsova T, Cubbage M, Curry CV.

Int J Clin Exp Pathol. 2014 Aug 15;7(9):6225-30.

15.

Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.

Ribera JM, Ortega JJ, Oriol A, Granada I, Hernández-Rivas JM, Parody R, Bethencourt C, Rivas C, Bastida P, del Potro E, González-Valentín ME, Moreno MJ, Besalduch J, Fernández-Calvo J, Tormo M, Arias J, Molinés A, Sanz MA, Maldonado J, Millá F, Feliu E, San Miguel JF; PETHEMA Group, Spanish Society of Hematology..

Haematologica. 2002 Feb;87(2):154-66.

16.

T-cell receptor-γ in gamma-delta phenotype cutaneous T-cell lymphoma can be accompanied by atypical expression of CD30, CD4, or TCRβF1 and an indolent clinical course.

Vin H, Talpur R, Tetzlaff MT, Duvic M.

Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):e195-200. doi: 10.1016/j.clml.2014.06.024. No abstract available.

PMID:
25088535
17.

Cross-lineage expression in 505 patients with acute lymphoblastic leukemia by multiparametric flow cytometry analysis.

Wang XB, Du W, Xia L, Zheng JE, Liu J, He YL, Sun ZM, Huang SA.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Dec;17(6):1419-23.

PMID:
20030918
18.

Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762).

Westbrook CA, Hooberman AL, Spino C, Dodge RK, Larson RA, Davey F, Wurster-Hill DH, Sobol RE, Schiffer C, Bloomfield CD.

Blood. 1992 Dec 15;80(12):2983-90.

19.

[Classical and molecular cytogenetic abnormalities in 124 pediatric patients with acute lymphoblastic leukemia].

Chai YH, Lü H, Li JQ, Lu J, Xiao PF, He YX, Shao XJ.

Zhonghua Er Ke Za Zhi. 2007 Sep;45(9):684-6. Chinese.

PMID:
18021563
20.

[Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].

Lu XT.

Beijing Da Xue Xue Bao. 2013 Apr 18;45(2):327-32. Review. Chinese.

Supplemental Content

Support Center